SOST and chronic kidney disease: Furthermore, recent pre-clinical studies have demonstrated that other agents, including sodium thiosulfate, denosumab, SNF472, sclerostin antibody, and genetically activated klotho, also potentially inhibit VC in patients with CKD [56, 183, 228, 229].